PARKVILLE, Missouri— Bond Biosciences, Inc., a clinical-stage, privately held biopharmaceutical company today announced a successful meeting with the U.S. Food and Drug Administration (FDA) following a scheduled pre-IND meeting with the Office of Cardiology, Hematology, Endocrinology, and Nephrology, Division of Nonmalignant Hematology to seek advice on the BBI-001 development program...
research News
Results of a retrospective analysis showed a significantly elevated risk of bone fractures in a population-based cohort of patients with myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV), compared with the overall population. These findings were published in Leukemia and Lymphoma. The Philadelphia chromosome-negative MPNs, characterized by clonal proliferation of 1 or more...
Melbourne, Australia – A drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep apnea and needing surgery, according to a new study. The international research trial, led by Murdoch Children’s Research Institute (MCRI) and...
Orchard Park, NY – A new research perspective was published in Oncotarget in January 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.” Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in...
CHESTNUT HILL, Mass. – Boston College Assistant Professor of Biology Emrah Altindis has been awarded a five-year, $2.5-million grant from the National Institutes of Health to study viral insulins and mechanisms related to IGF-1 receptor protein inhibition and its potential applications in cancer treatment. Altindis said he and the researchers...
Boston, Mass. – Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapies for sickle cell disease, including one that uses a type of novel genome editing technology. The new therapies...
Boston, Mass. — Each year, approximately 2,000 people die annually of gallbladder cancer (GBC) in the U.S., with only one in five cases diagnosed at an early stage. With GBC rated as the first biliary tract cancer and the 17th most deadly cancer worldwide, pressing attention for proper management of...
Boston, Mass. — Dennis Jones, PhD, assistant professor of pathology & laboratory medicine at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, $330,000 grant from the Department of Defense for his research, “Enhancing Lymphatic Function with Transplanted Muscle Cells after Bacterial Infection.” Lymphedema is a...
BOSTON, Mass. — David T. Felson, MD, MPH and Tuhina Neogi, MD, PhD professors of medicine at Boston University Chobanian & Avedisian School of Medicine and of epidemiology at the School of Public Health, have been awarded a U19 grant from the NIH’s National Institute on Aging. The five-year, $46...
Boston, Mass. – Identifying genetic variants and the role they play in predisposing people to Alzheimer’s disease can help researchers better understand how to treat the neurodegenerative condition for which there is currently no cure. A new study led by Boston University School of Public Health (BUSPH) and UTHealth Houston...